drugset
drugset / Trial / NCT02805556

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

NCT02805556 ↗

Phase 1 Completed 36 enrolled ViiV Healthcare GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing

Timeline

Start
2016-03-15
Primary completion
2016-05-05
Completion
2016-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostemsavir Other / unclassified — Oral
Subject TEMSAVIR Small molecule — Intravenous

Indications

HIV infectious disease